



# WEALTHMAKERS

Chief Analytics Officer: Thomas Ronk

(OTC: NVLX)

**Bullish**

---

### Overview

Recent Price	\$ .1295
52 Week Range	\$0.03 - \$0.22
1 Month Range	\$0.097-\$0.155
Avg Daily Volume	1,889,250
PE Ratio	0.0

---

### Earnings Per Share

Year	EPS
2014(E)	N/A

---

### Capitalization

Shares Outstanding	593MM
Market Capitalization	\$76.85MM

---

### Predictive Range

Expected Movement \$0.24 - \$1.90



## Nuvilex, Inc.

Nuvilex, Inc. (OTC: NVLX) is an international biotechnology firm focused on developing and preparing to commercialize treatments for cancer and diabetes built on a proprietary cellulose-based live-cell encapsulation platform, known as Cell-in-a-Box™, that is therapeutically valuable. Nuvilex is leveraging its cancer biology and clinical oncology research experience and expertise, particularly for use in oncology treatments, in addition to initiating the use of the platform in developing oncology applications of medical marijuana. Nuvilex is building a strong foundation in the medical marijuana space with some of the leading experts in the field; this could ultimately position Nuvilex to emerge as a leader in the multi-billion dollar marijuana industry. Nuvilex's subsidiary, Medical Marijuana Sciences, Inc., appointed Mark L. Rabe, M.D., Chief Medical Officer (CMO) of California's largest network of physician-owned medical cannabis evaluation centers, to the position of Chairman of its Scientific Advisory Board. In his position as CMO of the network of cannabis evaluation centers, Dr. Rabe has helped provide over 100,000 medical Cannabis recommendations to patients in 20 different clinics across the state. In addition, Richard M. Hyslop, Ph.D. has agreed to join the Scientific Advisory Board of Medical Marijuana Sciences. Dr. Hyslop, Professor of Chemistry and Biochemistry at the University of Northern Colorado, has expertise in anti-cancer drug design, the metabolism of anti-cancer drugs and studies of enzymes and enzyme-catalyzed reactions in biological tissues. Dr. Hyslop's experience with cancer drugs and enzymology will prove to be invaluable in pursuing the goals of Medical Marijuana Sciences that include developing treatments, which employ constituents of Cannabis together with the Cell-in-a-Box™ live-cell encapsulation technology, whose rights were acquired by Nuvilex in 2013, for some of the deadliest forms of cancer. Dr. Hyslop's location in the most high profile state in the country that has legalized the use of marijuana for medicinal purposes could be a further boon to the Company's R&D efforts.

## Investment Highlights

- **PATTERN SCAN** predicts the price of NVLX expected to move up in the coming weeks based on the appearance of a 'Trend Line Break(3)' pattern. Specifically, a ICM Cloud Bounce variant of Trend Line Break(3) has been detected. The target is \$0.24.
- **SQUEEZETRIGGER** predicts that because NVLX closed above \$0.083, we expect a short squeeze to begin that could quickly drive the price of NVLX considerably higher.
- **VALUATION** NVLX has a current value of \$1.90 which means the stock is undervalued compared to its Price of \$0.1295.

## How WealthMakers Market Reads Work:

WealthMakers Market Reads™ provide you with market performance predictions based on proprietary technologies, trading algorithms and data to help you make better, more informed investment decisions. Here's a quick review of our predictive technologies:

- **EARNINGS** Most stock price histories show random or unpredictable movements around earnings reports. But some repeat the same pattern quarter after quarter, year after year. Earnings predicts probability, price move and length of move before and after all US stock earnings reports.
- **FRICTION FACTOR** Friction Factor is based on the relationship between the price of a stock and the volume at which it's bought and sold. Normal and abnormal Friction factor patterns can help you time your buying and selling decisions for maximum earnings potential.
- **GATS** The Global Automated Trading System (GATS) combines neural networks and genetic algorithms to reduce investment risks. GATS selects the highest probability trades in stocks, bonds, options, commodities, currencies and private equities, delivering precise, predictive and profitable data.
- **GROUP SECTOR** Certain institutions can exert buying or selling pressure over an entire industry group, pushing prices higher. Group Sector identifies stocks that most closely match their group's movement and generate powerful group consensus trading signals to help you profit from the herd mentality.
- **PATTERN SCAN** This technology automatically tracks "Trigger Events" that positively or negatively affect the value of a stock — or its perceived value among analysts — ranging from price fluctuations to natural disasters and political shifts. The results reveal patterns that can predict market movements.
- **EVENTS** Events describe the current technical situation in your stock. It displays the technicals, trend conditions and seasonal factors and automatically discovers how that stock has performed in the trading days following the occurrences of the event or combination of events. This technology automatically scans using complex historical queries based on what event is taking place right now in the stock. It then displays the probability, expected return and number of trading days for the expected move.
- **RegSHO NAKED SHORTS** Tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions
- **SEASONALITY** Seasonality analyzes more than 20 years of data to determine if stocks have a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias.
- **SQUEEZE TRIGGER** Our proprietary database of more than 3,500,000,000 short sale transactions allows us to calculate the exact price at which the total short interest is short in each stock. Squeeze Trigger Alerts let you know exactly when a short squeeze will start and how to trade profitably.
- **VALUATION** A stock's value is a function of its forecasted earnings per share and forecasted earnings growth, as well as profitability, interest and inflation rates. Valuation use these metrics to determine at what price a stock is undervalued or overvalued, so that you can make investment decisions accordingly.
- **INSIDER** Significant stock sales or purchases by company "insiders" (officers or directors) can be a predictor of future price movements — up or down. The Insider strategy tracks these actions and correlates them with historical data to give you an investment edge.


# Squeeze Trigger

Calculates the exact price at which a short squeeze will start.

Nuvilex Inc. (OTC: NVLX) has just triggered an alert where NVLX is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. Given the amount that short sellers need to cover, it is predicted that NVLX could go up dramatically by February 14, 2014

The Cumulative Squeeze Trigger price for NVLX is 0.083.

This means that when NVLX closes above \$0.083, we expect a short squeeze to begin that could quickly drive the price of NVLX considerably higher.




- NVLX has hit the Squeeze Trigger price of 0.083.
- Based on the amount of value that short sellers need to cover, a short squeeze is predicted at \$0.083.
- Short Sellers will be forced to buy to cover short positions, sending the price higher.

## Pattern Scan

Tracks "Trigger Events" that positively or negatively affect the value of a stock.

Nuvilex Inc. (OTC: NVLX) is predicted to go up in coming weeks based on bullish technical trends that have appeared in the recent performance of the stock. NVLX has demonstrated Trend Line Break(3) strategy ICM Cloud Bounce with a strength of 4.0/5. The higher the strength, the higher the probability of an accurate prediction.



- The price of NVLX expected to move up in the coming weeks.
- PatternScan has detected that a 'ICM Cloud Bounce' pattern has appeared.
- Specifically, a ICM Cloud Bounce variant of Trend Line Break(3) has been detected.
- This indicates a high probability that NVLX will move up in the coming weeks.

## Squeeze Trigger

We have a proprietary database of all trading in US stocks and maintain massive databases of short sale and naked short sale time and sales data, along with short squeeze SqueezeTrigger prices. We are the only firm that knows the exact price that a short squeeze will start in every US stock.

Date	ShortVolume	TotalVolume	Percent	SqueezeTrigger	SValue
1/17/14	393,490	2,196,086	17.92%	\$0.1287	\$50,642
1/16/14	353,155	1,349,000	26.18%	\$0.1321	\$46,652
1/15/14	418,735	1,995,600	20.98%	\$0.1336	\$55,943
1/14/14	373,137	2,221,600	16.80%	\$0.1345	\$50,373
1/13/14	561,287	2,658,900	21.11%	\$0.1336	\$74,651
1/10/14	854,210	3,948,500	21.63%	\$0.1286	\$117,027
1/9/14	3,938,021	10,606,200	37.13%	\$0.1429	\$543,447
1/8/14	2,347,678	5,226,600	44.92%	\$0.1279	\$307,546
1/7/14	1,250,923	2,988,200	41.86%	\$0.1200	\$152,613
1/6/14	936,947	3,613,500	25.93%	\$0.1122	\$114,308
1/3/14	811,816	2,479,100	32.75%	\$0.1122	\$93,359
1/2/14	1,032,309	1,910,500	54.03%	\$0.1062	\$111,489
12/31/13	744,944	3,691,500	20.18%	\$0.1015	\$76,729
12/30/13	408,569	1,978,400	20.65%	\$0.1036	\$43,308
12/27/13	319,939	1,792,800	17.85%	\$0.1062	\$34,233
12/26/13	641,891	1,398,200	45.91%	\$0.1085	\$69,966
12/24/13	117,634	259,800	45.28%	\$0.1090	\$12,940
12/23/13	505,858	1,682,400	30.07%	\$0.1090	\$56,150
12/20/13	697,594	1,643,200	42.45%	\$0.1138	\$76,735
12/19/13	431,136	1,388,900	31.04%	\$0.1138	\$49,150
12/18/13	50,227	756,800	6.64%	\$0.1157	\$5,927
12/17/13	443,149	2,076,300	21.34%	\$0.1197	\$53,621
12/16/13	355,721	1,144,500	31.08%	12.34%	\$43,754
12/13/13	303,725	902,800	33.64%	12.50%	\$38,269
12/12/13	490,370	1,013,100	48.40%	12.53%	\$61,296
12/11/13	656,809	1,240,200	52.96%	12.65%	\$82,758
12/10/13	709,274	1,416,000	50.09%	12.75%	\$90,787
12/9/13	1,076,650	1,511,500	71.23%	12.90%	\$139,965
12/6/13	533,148	1,165,200	45.76%	12.76%	\$68,029
12/5/13	141,212	712,100	19.83%	12.67%	\$17,891
12/4/13	251,154	606,400	41.42%	12.96%	\$32,399
12/3/13	405,440	1,021,200	39.70%	12.96%	\$53,518
12/2/13	428,664	1,365,200	31.40%	13.24%	\$57,012
11/29/13	232,393	947,200	24.53%	13.21%	\$30,908
11/27/13	441,727	1,283,400	34.42%	12.89%	\$57,866
<b>Total</b>	<b>397,511,503</b>	<b>1,044,281,500</b>	<b>38.07%</b>	<b>\$0.0832</b>	<b>\$33,074,470</b>
*Total includes data back to 8-3-09. Chart truncated for viewing.					

## Friction Factor

Friction Factor determines if there is normal or abnormal behavior in the price action of the stock when compared to the buying vs. selling trading statistics. It shows us how many more shares of buying than selling it takes to move a stock higher by 1 cent, or how many more shares of selling than buying it takes to drop a stock by 1 cent.

<b>Date</b>	<b>Change</b>	<b>BuyVol</b>	<b>SellVol</b>	<b>NetVol</b>	<b>Friction</b>
2014/01/17	-\$0.0043	922,739	1,173,277	-250,538	-582,647
2014/01/16	\$0.0012	484,413	862,993	-378,580	Bullish Bias
2014/01/15	-\$0.0014	782,983	1,050,625	-267,642	-1,911,729
2014/01/14	-\$0.0005	1,120,077	1,081,379	38,698	Bearish Bias
2014/01/13	\$0.0045	1,415,463	1,243,182	172,281	382,847
2014/01/10	-\$0.0085	1,310,792	2,634,361	-1,323,569	-1,557,140
2014/01/09	\$0.0050	4,899,941	5,275,962	-376,021	Bullish Bias
2014/01/08	\$0.0096	2,984,704	2,236,064	748,640	779,833
2014/01/07	\$0.0000	1,744,542	1,240,905	503,637	Abnormal
2014/01/06	\$0.0055	2,025,385	1,542,066	483,319	878,762
2014/01/03	\$0.0000	996,399	1,426,081	-429,682	Abnormal
2014/01/02	\$0.0125	1,235,231	655,587	579,644	463,715
2013/12/31	-\$0.0020	1,401,177	2,276,359	-875,182	-4,375,910
2013/12/30	-\$0.0015	835,880	1,140,281	-304,401	-2,029,340
2013/12/27	-\$0.0035	431,422	1,361,319	-929,897	-2,656,849
2013/12/26	-\$0.0013	642,955	755,339	-112,384	-864,492
2013/12/24	-\$0.0002	100,462	157,388	-56,926	-2,846,300
2013/12/23	\$0.0015	733,766	903,038	-169,272	Bullish Bias
2013/12/20	-\$0.0027	606,790	1,036,369	-429,579	-1,591,033
2013/12/19	-\$0.0039	567,945	795,278	-227,333	-582,905
2013/12/18	-\$0.0044	276,096	480,689	-204,593	-464,984
2013/12/17	-\$0.0025	583,699	1,491,473	-907,774	-3,631,096
2013/12/16	-\$0.0022	449,340	692,619	-243,279	-1,105,814
2013/12/13	-\$0.0013	326,745	575,961	-249,216	-1,917,046
2013/12/12	-\$0.0005	601,900	411,219	190,681	Bearish Bias
2013/12/11	\$0.0000	629,607	610,462	19,145	Abnormal
2013/12/10	-\$0.0039	565,669	821,844	-256,175	-656,859
2013/12/09	\$0.0029	869,442	641,988	227,454	784,324
2013/12/06	\$0.0010	612,711	552,561	60,150	601,500
2013/12/05	-\$0.0026	192,162	520,032	-327,870	-1,261,038
2013/12/04	-\$0.0008	266,241	340,160	-73,919	-923,988
2013/12/03	-\$0.0031	554,058	467,170	86,888	Bearish Bias
2013/12/02	-\$0.0005	507,728	831,655	-323,927	-6,478,540
2013/11/29	\$0.0050	523,397	423,830	99,567	199,134
2013/11/27	-\$0.0040	446,641	836,838	-390,197	-975,493
2013/11/26	\$0.0010	706,455	1,039,619	-333,164	Bullish Bias
2013/11/25	\$0.0065	1,664,504	1,080,121	584,383	899,051
2013/11/22	-\$0.0035	309,436	869,593	-560,157	-1,600,449

## Valuation

Value is a measure of a stock's current worth. NVLX has a current value of \$1.90 per share. Therefore, it is undervalued compared to its Price of \$0.1295 per share. Value is computed from forecasted earnings per share, forecasted earnings growth, profitability, interest, and inflation rates. Value increases when earnings, earnings growth rate and profitability increase, and when interest and inflation rates decrease.

## General Results

Past success in predictions regarding all predictions on the WealthMakers platform.

Our prediction engine has a track record that is second to none. See for our results.

<b>Read Type</b>	<b>Avg Return</b>	<b>Avg Maturity Days</b>	<b>Hits</b>	<b>Misses</b>	<b>% Accurate</b>
Group Correlation	7.461	15.0	1280	72	94.67%
SqueezeTrigger	12.524	22.48	6796	397	94.48%
Insider	14.679	68.38	7128	450	94.06%
Valuation	14.484	26.96	4201	302	93.29%
Seasonality	7.605	15.08	37532	3523	91.42%
PatternScan	8.272	11.23	95516	13894	87.30%
Events	7.127	11.1	2861	461	86.12%
GATS	5.43	7.98	34040	6045	84.92%
Earnings	8.806	10.28	20387	4084	83.31%
Friction Factor	7.232	3.65	4913	1394	77.90%
Naked Shorts	14.728	10.73	1758	499	77.89%

## Prediction Success

Past success in predictions regarding Nuvilex Inc..

- Nuvilex Inc (OTC:NVLX), Down By 73.60% (\$0.13) From \$0.178 After Report Predicted Stock Would Go Down Due To Bearish Conditions Wednesday, May 15, 2013, 7:16:00 AM

## Recent Headlines

- Nuvilex and Medical Marijuana Companies Keep an Eye on Florida as Crucial Swing State in Cannabis Debate Marketwired (Thu, Jan 16)
- Nuvilex's Medical Marijuana Sciences Prepares to Enhance Industry's Research With Cell-in-a-Box(TM) Marketwired (Tue, Jan 14)
- Nuvilex Making Great Strides in Medical Marijuana Initiatives Accesswire (Mon, Jan 13)
- Nuvilex Growing Medical Marijuana Sciences to Lead Marijuana Research Industry Marketwired (Thu, Jan 9)
- Nuvilex's Medical Marijuana Sciences Ready to Welcome New York State's Approval of the Drug Marketwired (Tue, Jan 7)
- Nuvilex, Inc. Subsidiary Medical Marijuana Sciences, Inc. Appoints University of Northern Colorado Professor, Richard M. Hyslop, Ph.D., to Scientific Advisory Board GlobeNewswire (Mon, Jan 6)
- Nuvilex's Medical Marijuana Subsidiary Poised for Growth in the New Year Marketwired (Fri, Jan 3)
- Dr. Mark L. Rabe Develops Charter for Scientific Advisory Board of Nuvilex's Subsidiary, Medical Marijuana Sciences, Inc. GlobeNewswire (Mon, Dec 30)
- Nuvilex Lands Leading Figure in Medical Marijuana Field as Chairman of Subsidiary's Scientific Advisory Board Marketwired (Mon, Dec 23)
- NUVILEX, INC. FinancialsEDGAR Online Financials(Sat, Dec 21)
- Nuvilex Readies for Late-Stage Trials as NCI Seeks New Pancreatic Cancer Drugs Accesswire (Fri, Dec 20)
- Nuvilex's Provides Progress Update on Cell Cloning Being Performed by Inno Biologics GlobeNewswire (Thu, Dec 19)
- Nuvilex's Medical Marijuana Research Could Use Cell Encapsulation Technology to Address Brain Cancers Marketwired (Wed, Dec 18)
- Nuvilex to Answer Increasing Calls for Better Pancreatic Cancer Treatment Without Gemcitabine Marketwired (Mon, Dec 16)

## QUESTIONS?

ACCOUNT SUPPORT 516-858-1113  
EMAIL - [support@wealthmakers.com](mailto:support@wealthmakers.com)

## About WealthMakers

WealthMakers gives institutional and individual investors an exclusive advantage in making precise, predictive and profitable trading decisions. Our proprietary technologies — Earnings, Seasonality, Squeeze Trigger, Group Sector and GATS — apply artificial intelligence, proprietary algorithms, market data and research to help our clients realize exponential returns. Find out more at [WealthMakers.com](http://WealthMakers.com).

All material herein was prepared by WealthMakers, based upon information believed to be reliable. The information contained herein is not guaranteed by WealthMakers to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WealthMakers is not a registered investment advisor in the State of California. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. WealthMakers or its affiliates may receive compensation from independent third parties, or from the companies mentioned, for data provided in this report or related services. WealthMakers affiliates, officers, directors and employees do not own shares of the company mentioned in this report, but may from time to time buy/sell the shares discussed in this opinion and may profit from those trades. Market commentary provided by Thomas Ronk, a registered investment advisor and commodities trading advisor in California. WealthMakers will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment.

All Rights Reserved. Copyright 2014 WealthMakers